Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.32, marking a -3.36% move from the previous day. This change lagged the S&P 500's daily loss of 0.13%. On the other hand, ...
Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results